Samtidig behandling med andre potente CYP3A- hæmmere, fx itraconazol, forventes også at øge følsomheden for fluticason og risikoen for systemiske bivirkninger.
Co-treatment with other potent CYP3A inhibitors, such as itraconazole, is also expected to increase the systemic fluticasone propionate exposure and the risk of systemic side-effects.